Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.7% – Here’s What Happened

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) dropped 2.7% during trading on Wednesday . The stock traded as low as $12.50 and last traded at $12.50. Approximately 283 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,590 shares. The stock had previously closed at $12.85.

Finch Therapeutics Group Stock Performance

The company’s 50-day moving average price is $13.48 and its 200 day moving average price is $13.24. The stock has a market capitalization of $20.13 million, a PE ratio of -1.42 and a beta of 1.18.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.